# Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma

> **NCT03732547** · PHASE2 · UNKNOWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 60 (estimated)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** PD-1 mAb
- **DRUG:** PolyIC

## Key facts

- **NCT ID:** NCT03732547
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-22
- **Primary completion:** 2021-10-22
- **Final completion:** 2023-10-22
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2018-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03732547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03732547, "Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03732547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*